The rare disease landscape has changed over the last several years. The pharmaceutical industry has begun to pay more attention to rare diseases, drawn by government incentives and the greater likelihood that treatments will be successful.
The launch of a rare disease treatment needs a different approach from the standard launch framework.
Hit the download button to get a PDF copy of the report
